论文部分内容阅读
AbbottLaboratories公司的注射用paricalcitol（商品名Zemplar）获美国许可用于治疗和预防慢性肾衰病人的甲状旁腺功能亢进。本品是第一个获得许可用于这一适应证的维生素D类似物。经三项安慰剂对照研究发现，用本品治疗的慢性肾衰病人6周内其平均甲状旁腺激素水平下降了30％。
Abbott Laboratories’ injectable paricalcitol (Zemplar) is a U.S. licensed drug for the treatment and prevention of hyperparathyroidism in patients with chronic renal failure. This product is the first vitamin D analogue licensed for this indication. Three placebo-controlled studies found that patients treated with this product had a 30% reduction in mean parathyroid hormone levels within 6 weeks.